Big Pharma
11 December 2025 Israeli drug maker bows to FTC pressure, removing scores of “improperly listed” patents in boon for generic manufacturers.
9 December 2025
2 December 2025
27 November 2025
26 November 2025
21 November 2025
20 November 2025
Latest Features
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
More News
20 November 2025 A PTAB dispute over $29.5bn drug reaches a dramatic conclusion, at a critical time ahead of the drug's US patent expiration.
20 November 2025 A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
19 November 2025 The court rules that Duke University and Allergan’s patent lacked sufficient written description, in the wake of stricter post-Amgen Section 112 standards.
18 November 2025 An EUIPO appeals board sided with the French pharma company’s vaccine division in a dispute with an India-based biotech company over Sanofi’s ‘Covaxis’ mark.
14 November 2025 In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.
13 November 2025 Inconsistent Bolar interpretations and tougher trial disclosures are tightening the squeeze on innovators in life sciences, counsel told LSPN Europe. Tom Phillips reports.
13 November 2025 Pharma company tells court generics rival’s petition is “not the subject of any legal conflict”, as it reassures investors that a $12bn biotech acquisition will deliver growth.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox